Brief: Daewoong Says Long-Acting Niclosamide Shows Promise Against Upcoming COVID-19 'Twindemic'
27/10/2020 13:13
Oct 27 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL'S LONG-ACTING NICLOSAMIDE SHOWS
HIGH
PROMISE AGAINST UPCOMING COVID-19 'TWINDEMIC'
* DAEWOONG PHARMA - INFLUENZA A (IVA) ANIMAL MODEL CONFIRMED
75%
CLINICAL SYMPTOM IMPROVEMENT COMPARED TO CONTROL GROUP
* DAEWOONG PHARMA - BROAD ANTIVIRAL EFFICACY RESULTS AGAINST
SARS-COV-2 AND IVA WERE PRESENTED AT ISIRV-AVERAGE CONFERENCE
Source text for Eikon: ID:nPnZmnMVa
Further company coverage: 069620.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier